Ozempic could be up next for Medicare price negotiations

Wall Street analysts are speculating that the popular diabetes and weight loss medication Ozempic could be subject to federal government price negotiations next year as part of the Department of Health and Human Service‘s new program to lower Medicare prescription prices.

Last week, the Biden administration announced the final negotiated prices for the first 10 drugs selected as the most expensive medications covered by Medicare as part of the negotiation program established by the 2022 Inflation Reduction Act, which was passed by Democrats.

Under the legislation, the Centers for Medicare and Medicaid Services have the ability to negotiate directly with pharmaceutical companies for the price of medications — and impose punitive taxes if the drugmakers refuse to comply. During the first round of negotiations, the

Continue reading